logo
Nvidia's China return buys time for Beijing to boost its chip drive

Nvidia's China return buys time for Beijing to boost its chip drive

CNBC3 days ago
As semiconductors have become a geopolitical hot potato over the past few years, it's no surprise that Nvidia , the leader in artificial intelligence-related chips, has been caught up in escalating tensions between the U.S. and China. When Nvidia returned to the China market last week , seemingly with the blessing of Washington, it sparked debate over the strategic implications for the U.S.' dominance in AI and China's own focus on boosting its domestic chip and tech industry. For the U.S., Nvidia's return could help cement American strength in AI globally, experts told CNBC. For China, it could buy the country time as it continues on its own path to build Nvidia rivals and keep pace with AI software development. It's a tricky relationship, underscoring the strategic importance of the graphics processing units (GPUs) that Nvidia designs and that currently underpin the world's AI. "The relationship is symbiotic but I do believe China needs the U.S. technology more at this moment in time," Daniel Newman, CEO of Futurum, told CNBC's "The China Connection" last week. Nvidia's warnings Earlier this year, the U.S. government restricted exports of Nvidia's H20 chip to China. The product, a less-advanced version of Nvidia's leading hardware, had been created to comply with previous U.S. export restrictions. Washington has expressed concerned that these chips could be used in areas such as advancing the Chinese military and China's own AI industry. Nvidia took a $4.5 billion writedown on the unsold inventory and warned the China restrictions could impact billions of dollars of potential sales. Jensen Huang, the CEO of Nvidia, has been critical of export curbs . He has said it would be a "tremendous loss" for Nvidia not to participate in China and that rival Huawei would be able to fulfil the needs of the country in its absence. Huang has argued that the restrictions could boost China's domestic semiconductor industry and that it risks eroding America's technological edge. That message appears to have got through to the White House. Nvidia said last week that it received backing from the U.S. government to resume sales of H20 in China. How the move will benefit the U.S. From a business perspective, Nvidia is expected to gain. But for Washington, the move is more strategic. "We want to keep having the Chinese use the American technology stack, because they still rely upon it," Commerce Secretary Howard Lutnick told CNBC last week. Nvidia has managed to gain a formidable position in the market for semiconductors required to train and run AI applications, not just because of its hardware but also because of the popularity of its software platform known as CUDA, that developers build on. This creates an "ecosystem" around Nvidia's products which has proven sticky for its users. The return of the H20 to the world's second-largest economy will "buy China time" to boost its domestic industry, according to Pranay Kotasthane, deputy director at the Takshashila Institution. "But it will also buy the U.S. companies some respite. China is Nvidia's largest market and is home to 50 per cent of AI developers according to Jensen Huang. If that path is completely closed, American firms like Nvidia will find it difficult to raise revenues and re-invest them in the next round of research and development," Kotasthane said. "It might be justifiable to restrain access to the most advanced chips but to expand the scope of the restrictions doesn't make strategic sense." China domestic chips in focus Huawei has been China's leading player in developing AI-focused chips. The country's technology companies are using some of Huawei's hardware but the firm has yet to overtake the dominance of Nvidia's latest chips. One possible outcome is that U.S. export curbs will accelerate China's domestic efforts. China has been looking to boost its domestic semiconductor industry with a particular focus on AI chips. There are a whole host of startups working on new products in the country. Nvidia's return to China could slowdown that progress. "If Nvidia's chips are made available to Chinese firms, it could weaken momentum behind domestic chip projects, cut off capital, and delay progress in domestic Chinese hardware. This retains U.S. tech influence over global AI rails," Tejas Dessai, director of research at Global X ETFs, told CNBC by email. Ultimately, it all goes back to Nvidia's software which keeps developers locked into its hardware. "Chinese model developers still prefer to use Nvidia hardware, because the domestic alternative AI stack, particularly the software development environment from Huawei is still difficult to use and lacks the depth and flexibility of Nvidia's offering," Paul Triolo, a partner at DGA-Albright Stonebridge Group, told CNBC by email. Can China catch up to Nvidia? Still, China's direction of travel and its quest for domestic providers of AI chips is unlikely to change. "Eventually Chinese AI model developers will have to transitions to a domestic AI stack," Triolo said. Nvidia's chips have proved very effective at training huge AI models that require massive amounts of data to be processed. The actual running of those AI model in products like chatbots is known as inferencing. This process may require a different type of chip, which Chinese tech giants as well as startups are working on. "In chips, China's opportunity could come when the focus shifts to inference. That's when demand for lower cost, efficient processors could scale, and we believe custom chip programs from big Chinese tech companies could ultimately serve that demand," Dessai of Global X ETFs said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

Yahoo

time7 minutes ago

  • Yahoo

Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says

By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Solve the daily Crossword

Europeans and Iran meet in Istanbul as the return of sanctions looms over nuclear deadlock
Europeans and Iran meet in Istanbul as the return of sanctions looms over nuclear deadlock

Boston Globe

time9 minutes ago

  • Boston Globe

Europeans and Iran meet in Istanbul as the return of sanctions looms over nuclear deadlock

The return of sanctions, known as a 'snapback' mechanism, 'remains on the table,' according to a European diplomat speaking on condition of anonymity due to the sensitivity of the talks. 'A possible delay in triggering snapback has been floated to the Iranians on the condition that there is credible diplomatic engagement by Iran, that they resume full cooperation with the IAEA (International Atomic Energy Agency), and that they address concerns about their highly-enriched uranium stockpile,' the diplomat said. European leaders have said sanctions will resume by the end of August if there is no progress on containing Iran's nuclear program. Advertisement Tehran, meanwhile, has said the U.S., which withdrew from the 2015 deal during President Donald Trump 's first term, needs to rebuild faith in its role in negotiations. Deputy Foreign Minister Kazem Gharibabadi said Iran's engagement was dependent on 'several key principles' that included 'rebuilding Iran's trust – as Iran has absolutely no trust in the United States.' In a social media post Thursday, he also said the talks shouldn't be used 'as a platform for hidden agendas such as military action.' Gharibabadi insisted that Iran's right to enrich uranium 'in line with its legitimate needs' be respected and sanctions removed. Advertisement Iran has repeatedly threatened to leave the Nuclear Nonproliferation Treaty, which commits it to refrain from developing nuclear weapons, if sanctions return. Friday's talks were being held at the deputy ministerial level, with Iran sending Deputy Foreign Minister Majid Takht-e Ravanchi. A similar meeting was held in Istanbul in May. The identity of the E3 representatives were not immediately clear but the European Union's deputy foreign policy commissioner was thought to be attending. The U.K., France and Germany were signatories to the 2015 deal, alongside the U.S., Russia and China. When the U.S. withdrew in 2018, Trump insisted the agreement wasn't tough enough. Under the original deal, neither Russia nor China can veto reimposed sanctions. Since the Israeli and U.S. strikes on Iran, which saw American B-52 bombers hit three nuclear sites, Iran's Foreign Minister Abbas Araghchi has accused the E3 of hypocrisy, saying they failed to uphold their obligations while supporting Israel's attacks. Against the backdrop of the conflict, which saw Iran respond with missile attacks on Israel and a strike on a U.S. base in Qatar, the road ahead remains uncertain. While European officials have said they want to avoid further conflict and are open to a negotiated solution, they have warned that time is running out. Tehran maintains it is open to diplomacy, though it recently suspended cooperation with the IAEA. A central concern for Western powers was highlighted when the IAEA reported in May that Iran's stockpile of uranium enriched to 60% – just below weapons-grade level – had grown to over 400 kilograms (882 pounds). Advertisement In an interview with Al Jazeera that aired Wednesday, Iranian President Masoud Pezeshkian said Iran is prepared for another war and reiterated that its nuclear program will continue within the framework of international law while adding the country had no intention of pursuing nuclear weapons. A spokesman for Iran's Atomic Energy Organization said Thursday the country's nuclear industry would 'grow back and thrive again' after the recent attacks by Israel and the U.S. Vahdat reported from Tehran, Iran. Associated Press writer Stephanie Lichtenstein in Vienna contributed to this report.

Trump signs bill to cancel $9 billion in foreign aid, public broadcasting funding

time15 minutes ago

Trump signs bill to cancel $9 billion in foreign aid, public broadcasting funding

WASHINGTON -- President Donald Trump signed a bill Thursday canceling about $9 billion that had been approved for public broadcasting and foreign aid as Republicans look to lock in cuts to programs targeted by the White House's Department of Government Efficiency. The bulk of the spending being clawed back is for foreign assistance programs. About $1.1 billion was destined for the Corporation for Public Broadcasting, which finances NPR and PBS, though most of that money is distributed to more than 1,500 local public radio and television stations around the country. The White House had billed the legislation as a test case for Congress and said more such rescission packages would be on the way. Some Republicans were uncomfortable with the cuts, yet supported them anyway, wary of crossing Trump or upsetting his agenda. Democrats unanimously rejected the cuts but were powerless to stop them. The White House says the public media system is politically biased and an unnecessary expense. Conservatives particularly directed their ire at NPR and PBS. Lawmakers with large rural constituencies voiced grave concern about what the cuts to public broadcasting could mean for some local public stations in their state. Some stations will have to close, they warned. Sen. Lisa Murkowski, R-Alaska, said the stations are 'not just your news — it is your tsunami alert, it is your landslide alert, it is your volcano alert.' On the foreign aid cuts, the White House argued that they would incentivize other nations to step up and do more to respond to humanitarian crises and that the rescissions best served the American taxpayer. Democrats argued that the Republican administration's animus toward foreign aid programs would hurt America's standing in the world and create a vacuum for China to fill. They also expressed concerns that the cuts would have deadly consequences for many of the world's most impoverished people. 'With these cuts, we will cause death, spread disease and deepen starvation across the planet,' said Sen. Brian Schatz, D-Hawaii.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store